
Gene knockout cell lines are generated using CRISPR-Cas9 based technology to precisely disrupt target genes, enabling functional genomics research, disease modeling, and target validation.
B3GAT3 (beta-1,3-glucuronyltransferase 3) encodes a glucuronyltransferase that catalyzes the formation of the glycosaminoglycan-protein linkage region of proteoglycans. It transfers glucuronic acid to specific terminal sugar acceptors during the final step of linkage-region biosynthesis. Through this enzymatic activity, B3GAT3 contributes to proteoglycan biosynthesis and the production of glycosaminoglycan-containing extracellular matrix components.
A human gastric carcinoma cell line established from a metastatic lymph node. It was originally derived from gastric cancer and described as an undifferentiated, mucin-producing tumor cell line.
Comprehensive quality control includes STR authentication, sterility testing (bacteria and fungi), and mycoplasma screening to ensure purity and performance. Genotype is confirmed by two rounds of PCR and Sanger sequencing, and complete validation reports are provided for make-to-order products.

Cas9 cell lines in our cell bank can stably express Cas9 protein. Each Cas9 Stable Cell Line is easy to use and enables gene knockout simply by transfecting gRNA, while transfection of gRNA and donor DNA results in gene knock-in or point mutations
These Cas9 stable cell lines have been used to construct the KO cell lines for various genes, gene KO efficiency 5-10 times improved.
Selected cells, low passages, good cell condition, high activity, applicable for all kinds of gene-editing experiments.

Targeted knockout region: EExon 2
Reference Transcript: NM_012200
Frameshift Mutation Strategy
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use






Simply fill out the form below to leave your inquiry
— we will respond within 24 Hours
* Name
* Institution
* Products & Services of Interest
If email is not available, how else can we reach you?
How did you hear about us?